Pacgen Reports Positive Results From Phase IIb Candidiasis Trial
Posted on: Friday, 6 June 2008, 09:01 CDT
Pacgen Biopharmaceuticals has announced positive results from its Phase IIb dose-ranging trial of PAC-113, a novel antifungal drug candidate.
The results demonstrated that PAC-113 is effective in the treatment of oral Candidiasis and compares favorably to the efficacy demonstrated by Nystatin, a current standard of care.
The Phase IIb dose-ranging clinical trial was a randomized, examiner-blinded, four arm, parallel design trial comparing three different doses of PAC-113 to Nystatin, consisting of two week treatment phase and two week post-treatment/follow up phase.
The dose-ranging trial involved 223 seropositive HIV patients with oral Candidiasis, and was conducted at sites in the US and South Africa. The objectives of the trial were to identify an optimal dose of PAC-113 from among the three doses studied, and to determine the relative efficacy of this PAC-113 dose as compared to Nystatin in eliminating clinical signs and symptoms of oral Candidiasis. Additionally, safety and tolerance and the microbiological response of Candida albicans to treatment were also measured.
The optimal dose of PAC-113 demonstrated a 34% increase in the primary endpoint efficacy level (complete clinical cure rate at day 19) for the per protocol analysis as compared to Nystatin, and a 50% increase in the corresponding intent to treat analysis.
Secondary efficacy endpoints showed similar trends among the three PAC-113 doses and the Nystatin group. Results also confirmed that PAC-113 was generally safe and well-tolerated.
Source: Datamonitor
Related Articles
- First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
- TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
- Pacgen Announces Positive Results From Phase IIb Dose-Ranging Trial of PAC-113
- Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug
- Greer Launches Phase III Trial to Study Efficacy of Sublingual-Oral Immunotherapy in Patients With Allergic Rhinoconjunctivitis
- Pacgen Initiates Phase IIb Clinical Trial for Treatment of Oral Candidiasis
- Pacgen Presents Research Data at ACCP on Evaluation of a New Host Derived Synthetic Antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis
- TorreyPines Therapeutics Completes Phase I Trial for NGX426, a Novel Oral Treatment for Pain
- TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX426, a Novel Oral Therapy for Migraine and Neuropathic Pain
- Oral Candidiasis in Pediatric HIV Patients
 |
 |
User Comments (0)
RSS Feeds